Summit Therapeutics (SMMT) Tax Provisions (2017 - 2020)
Summit Therapeutics' (SMMT) quarterly Tax Provisions came in at -$21000.0 in Q4 2020, up 99.09% YoY from -$10548.0 in Q1 2020, and up 62.5% on a QoQ basis from -$56000.0 in Q3 2020.
Summit Therapeutics (SMMT) Tax Provisions (2017 - 2020) Analysis & Trends
Summit Therapeutics (SMMT) has 4 years of Tax Provisions data on file, last reported at -$21000.0 in Q4 2020.
- Quarterly Tax Provisions rose 99.09% year-over-year to -$21000.0 in Q4 2020, while the trailing twelve-month figure through Sep 2021 was -$21000.0 (up 99.16% YoY) and the FY2020 annual result came in at -$213000.0, down 691.67% from the prior year.
- Tax Provisions climbed to -$21000.0 in Q4 2020, from -$56000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $654347.7 in Q3 2018 to a low of -$2.3 million in Q4 2019.
- A 4-year average of -$805820.3 and a median of -$990828.5 in 2019 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2018 — Tax Provisions soared 139.53% — and 2019, when it slumped 305.77%.
- Tracing SMMT's Tax Provisions over 4 years: stood at -$1.9 million in 2017, then grew by 14.54% to -$1.7 million in 2018, then plunged by 39.31% to -$2.3 million in 2019, then soared by 99.09% to -$21000.0 in 2020.
- The last three Tax Provisions figures came in at -$21000.0 (Q4 2020), -$56000.0 (Q3 2020), and -$191000.0 (Q2 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -21,000.00 |
| Sep 30, 2020 | -56,000.00 |
| Jun 30, 2020 | -191,000.00 |
| Mar 31, 2020 | 55,000.00 |
| Dec 31, 2019 | -2.31 Mn |
| Oct 31, 2019 | -899,800.43 |
| Sep 30, 2019 | 111,000.00 |
| Jul 31, 2019 | -1.35 Mn |
| Mar 31, 2019 | -1.08 Mn |
| Oct 31, 2018 | -1.66 Mn |
| Jul 31, 2018 | 654,347.73 |
| Apr 30, 2018 | -1.33 Mn |
| Jan 31, 2018 | 265,490.64 |
| Oct 31, 2017 | -1.94 Mn |
| Jul 31, 2017 | -1.66 Mn |
| Apr 30, 2017 | -1.50 Mn |